title: The effect of zanoterone, a steroidal androgen receptor antagonist, in men with benign prostatic hyperplasia. The Zanoterone Study Group.
abstract: OBJECTIVE
  Zanoterone (100 to 800 mg.) versus placebo was studied in 463 patients with benign prostatic hyperplasia.
  
  
  METHODS
  Study end points were maximum urinary flow rate, American Urological Association symptom index, prostate volume, prostate specific antigen and sex steroid concentrations after 6 months of treatment.
  
  
  RESULTS
  Mean increases in maximum urinary flow rate were 2 to 3-fold over placebo, although only the 200 mg. group had significant results (1.7 ml. per second, p = 0.026). There were no statistically significant differences between the zanoterone and placebo groups in symptom index or prostate volume. Estradiol and testosterone concentrations, and the incidence of breast pain and gynecomastia increased significantly with zanoterone compared with placebo. Prostate specific antigen levels decreased significantly.
  
  
  CONCLUSIONS
  Zanoterone did not demonstrate a favorable risk-to-benefit profile for the treatment of benign prostatic hyperplasia.
authors.affiliation: Sanofi Research Division, Collegeville, Pennsylvania, USA.
authors.forename: B M
authors.initials: BM
authors.lastname: Berger
authors.forename: A
authors.initials: A
authors.lastname: Naadimuthu
authors.forename: A
authors.initials: A
authors.lastname: Boddy
authors.forename: H A
authors.initials: HA
authors.lastname: Fisher
authors.forename: J D
authors.initials: JD
authors.lastname: McConnell
authors.forename: D
authors.initials: D
authors.lastname: Milam
authors.forename: D
authors.initials: D
authors.lastname: Mobley
authors.forename: J
authors.initials: J
authors.lastname: Rajfer
mesh_terms: D000368:Aged; D000726:Androgen Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D004958:Estradiol / Q000097:blood; D006177:Gynecomastia / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D011278:Pregnanes / Q000009:adverse effects / Q000627:therapeutic use*; D011467:Prostate / Q000187:drug effects / Q000473:pathology; D017430:Prostate-Specific Antigen / Q000032:analysis; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D013739:Testosterone / Q000097:blood; D014563:Urodynamics / Q000187:drug effects
chemical_list: D000726:Androgen Antagonists; D011278:Pregnanes; D011720:Pyrazoles; D013739:Testosterone; D004958:Estradiol; D017430:Prostate-Specific Antigen; C060492:zanoterone